



MARKETSCAN HOSPITAL DRUG DATABASE STUDIES

Abbreviated Bibliography

Since 1988, healthcare researchers have used *Thomson Reuters MarketScan*[®] data to understand disease progression, treatment patterns, health outcomes, and their associated costs to patients, employers, health plans, and the government. Fully HIPAA-compliant, the *MarketScan* claims databases are the gold standard in proprietary databases used for healthcare research in the United States.

In 2007, we added the Solucient hospital databases to the *MarketScan* family. The value of the *MarketScan Hospital Drug Database* in helping healthcare researchers understand inpatient and outpatient drug utilization is demonstrated through a number of peer-reviewed publications.

Amin AN, Lenhart G, Princic N, Lin J, Thompson S, Johnston S. Retrospective administrative database study of the time period of venous thromboembolism risk during and following hospitalization for major orthopedic or abdominal surgery in real-world US patients. *Hospital Practice* 2011; 39(2): 7–17.

Itani KM, Merchant S, Lin SJ, Akhras K, Alandete JC, Hatoum HT. Outcomes and management costs in patients hospitalized for skin and skin-structure infections. *American Journal of Infection Control* 2011; 39(1): 42–9.

Amin AN, Lin J, Johnson BH, Schulman KL. Clinical and economic outcomes with appropriate or partial prophylaxis. *Thrombosis Research* 2010; 125(6): 513–7.

Amin AN, Lin J, Lenhart G, Schulman KL. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. *Thrombosis and Haemostasis* 2009; 102(2): 321–6.

Bae JP, Dobesh PP, McCollam PL, Khoyneshad A. Potential unrecognized costs of clopidogrel pretreatment in acute coronary syndrome. *Journal of Medical Economics* 2009; 12(4): 325–330.



- Kash BA, Ohsfeldt RL, Gamm LD. An attempt to forecast hospital market share using admission data. ***Journal of Healthcare Management*** 2009; 54(1): 44–55.
- Lee DW, Foster DA. The association between hospital outcomes and diagnostic imaging: Early findings. ***Journal of the American College of Radiology*** 2009; 6; 780–785.
- Ernst FR, Johnston JA, Pulgar S, He J, Ball DE, Young JK, Cooper LM. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: A database cohort study of hospital mortality, length of stay, and costs. ***Current Medical Research and Opinion*** 2007; 23(1): 235–44.
- Nallamothu BK, Young J, Gurm HS, Pickens G, Safavi K. Recent trends in hospital utilization for acute myocardial infarction and coronary revascularization in the United States. ***American Journal of Cardiology*** 2007; 99(6): 749–53.
- Wang C, Kereiakes DJ, Bae JP, McCollam P, He J, Griffin B. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. ***The Journal of Invasive Cardiology*** 2007; 19(10): 431–6.
- Burleigh E, Wang C, Foster D, Heller S, Dunn D, Safavi K, Griffin B, Smith J. Thromboprophylaxis in medically ill patients at risk for venous thromboembolism. ***American Journal of Health-System Pharmacy*** 2006; 63(20 Suppl 6): S23–9.
- Lin SJ, Lambert B, Tan H, Toh S. Frequency estimates from prescription drug datasets. ***Pharmacoepidemiology and Drug Safety*** 2006; 15(7): 512–20.
- Weiner BJ, Alexander JA, Shortell SM, Baker LC, Becker M, Geppert JJ. Quality improvement implementation and hospital performance on quality indicators. ***Health Services Research*** 2006; 41(2): 307–34.
- Proenca EJ, Rosko MD, Dismuke CE. Service collaboration and hospital cost performance: Direct and moderating effects. ***Medical Care*** 2005; 43(12): 1250–8.
- Belay ED, Holman RC, Maddox RA, Foster DA, Schonberger LB. Kawasaki syndrome hospitalizations and associated costs in the United States. ***Public Health Reports*** 2003; 118(5): 464–9.
- McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. ***American Journal of Health-System Pharmacy*** 2003. 60(12): 1251–6.
- Lage MJ, Barber BL, Bala M, Ball DE, Bowman L. A comparison of abciximab use in MCO and non-MCO populations. ***The American Journal of Managed Care*** 2001; 7(1): 53–62.
- Lage MJ, Barber BL, McCollam PL, Bala M, Scherer J. Impact of abciximab versus eptifibatide on length of hospital stay for PCI patients. ***Catheterization and Cardiovascular Intervention*** 2001; 53(3): 296–303.
- Lage MJ, Barber BL, McCollam PL, Bala M, Scherer J. Impact of abciximab versus tirofiban on hospital length of stay for PCI patients. ***Catheterization and Cardiovascular Intervention*** 2001; 52(3): 298–305.



- McCollam PL, Lage MJ, Bala M. A comparison of total hospital costs for percutaneous coronary intervention patients who receive abciximab versus tirofiban. ***Catheterization and Cardiovascular Intervention*** 2001; 54(2): 152–7.
- Lage MJ, Barber BL, Bala M, McCollam PL, Ball DE. Association between abciximab and length of stay in intensive care for patients undergoing percutaneous coronary intervention. A 2-stage econometric model in a naturalistic setting. ***Pharmacoeconomics*** 2000; 18(6): 581–9.
- Lage MJ, Barber BL, Bowman L, Ball DE, Bala M. Shorter hospital stays for angioplasty patients who receive abciximab. ***The Journal of Invasive Cardiology*** 2000; 12(4): 179–186.
- Sullivan KM, Belay ED, Durbin RE, Foster DA, Nordenberg DF. Epidemiology of Reye's Syndrome, United States, 1991–1994: Comparison of CDC surveillance and hospital admissions data. ***Neuroepidemiology*** 2000; 19(6): 338–44.
- Young JK, Foster DA. Cardiovascular procedures in patients with mental disorders. ***JAMA: The Journal of the American Medical Association*** 2000; 283(24): 3198; (correspondence) discussion 3198–9.

To contact Thomson Reuters regarding *MarketScan* research data, please call (866) 301-5419 or e-mail marketscan@thomsonreuters.com.

MarketScan is a registered trademark of Thomson Reuters (Healthcare) Inc.